The Asia Pacific Virtual Clinical Trials Market is expected to witness market growth of 7.9% CAGR during the forecast period (2020-2026).
The growing rate of neurological diseases like tumors, depression, epilepsy, Parkinson’s, and Alzheimer’s combined with the increasing geriatric population are components anticipated to boost the growth of the virtual clinical trial market over the forecast period. Growing clinical trials to find reliable and effective solutions to cure or decline and prevent the spread of neurological disorders and age-related diseases are components that will boost the growth of the virtual clinical trials market during the forecast period.
Furthermore, the instance of tropical and infectious diseases that need new medicines and drugs in numerous countries is a component anticipated to boost the growth of the virtual clinical trial market during the forecast period. Moreover, the modernization of clinical trials to improve productivity and collect information from many sources is a component anticipated to propel the growth of the clinical trial market in the next few years.
The oncology segment is expected to be the lead market during the forecast period. This is credited to the growing instances of cancer on a worldwide scale and the growing number of oncology clinical trials. Patients of cancer are the most unprotected during the outbreak of COVID-19. Examiners and sponsors supervising oncology clinical trials have rapidly included remote and virtual trials to maintain the safety of patients and keep the trails going forward.
Also, researchers studying cancer confronting major challenges in patient recruitment. Till June 2019, around 14,000 oncology trials were recruited actively with a participation rate of 3% to 8% of possible participants, with a slight number in minority and geriatric populations. Less rate of enrollment presents risks to the effectiveness of particular clinical studies. It may hinder the advancement in treatment and related advantages to results. Therefore, the low rate of recruitment and the requirement for a different population for oncology clinical researches are expected to fuel the acceptance of virtual clinical trials.
Based on Study Type, the market is segmented into Interventional, Observational, and Expanded Access and Others. Based on Indication, the market is segmented into Oncology, Cardiovascular, Immunology, Gastrointestinal, Respiratory, Endocrinology, Ophthalmology and Other Indications. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include IQVIA Holdings, Inc., ICON PLC, Laboratory Corporation of America Holdings (Covance, Inc.), Dassault Systemes SE (Medidata Solutions, Inc.), Oracle Corporation, Parexel International Corporation (Pamplona Capital Management), PRA Health Sciences, Inc. (KKR & Co., Inc.), Medpace Holdings, Inc., Medable, Inc. and Clinical Ink, Inc. (G.I. Partners)
Scope of the Study
Market Segments Covered in the Report:
By Study Type
By Indication
By Country
Companies Profiled
Unique Offerings
The growing rate of neurological diseases like tumors, depression, epilepsy, Parkinson’s, and Alzheimer’s combined with the increasing geriatric population are components anticipated to boost the growth of the virtual clinical trial market over the forecast period. Growing clinical trials to find reliable and effective solutions to cure or decline and prevent the spread of neurological disorders and age-related diseases are components that will boost the growth of the virtual clinical trials market during the forecast period.
Furthermore, the instance of tropical and infectious diseases that need new medicines and drugs in numerous countries is a component anticipated to boost the growth of the virtual clinical trial market during the forecast period. Moreover, the modernization of clinical trials to improve productivity and collect information from many sources is a component anticipated to propel the growth of the clinical trial market in the next few years.
The oncology segment is expected to be the lead market during the forecast period. This is credited to the growing instances of cancer on a worldwide scale and the growing number of oncology clinical trials. Patients of cancer are the most unprotected during the outbreak of COVID-19. Examiners and sponsors supervising oncology clinical trials have rapidly included remote and virtual trials to maintain the safety of patients and keep the trails going forward.
Also, researchers studying cancer confronting major challenges in patient recruitment. Till June 2019, around 14,000 oncology trials were recruited actively with a participation rate of 3% to 8% of possible participants, with a slight number in minority and geriatric populations. Less rate of enrollment presents risks to the effectiveness of particular clinical studies. It may hinder the advancement in treatment and related advantages to results. Therefore, the low rate of recruitment and the requirement for a different population for oncology clinical researches are expected to fuel the acceptance of virtual clinical trials.
Based on Study Type, the market is segmented into Interventional, Observational, and Expanded Access and Others. Based on Indication, the market is segmented into Oncology, Cardiovascular, Immunology, Gastrointestinal, Respiratory, Endocrinology, Ophthalmology and Other Indications. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include IQVIA Holdings, Inc., ICON PLC, Laboratory Corporation of America Holdings (Covance, Inc.), Dassault Systemes SE (Medidata Solutions, Inc.), Oracle Corporation, Parexel International Corporation (Pamplona Capital Management), PRA Health Sciences, Inc. (KKR & Co., Inc.), Medpace Holdings, Inc., Medable, Inc. and Clinical Ink, Inc. (G.I. Partners)
Scope of the Study
Market Segments Covered in the Report:
By Study Type
- Interventional
- Observational
- Expanded Access
- Others
By Indication
- Oncology
- Cardiovascular
- Immunology
- Gastrointestinal
- Respiratory
- Endocrinology
- Ophthalmology
- Other Indications
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Companies Profiled
- IQVIA Holdings, Inc.
- ICON PLC
- Laboratory Corporation of America Holdings (Covance, Inc.)
- Dassault Systemes SE (Medidata Solutions, Inc.)
- Oracle Corporation
- Parexel International Corporation (Pamplona Capital Management)
- PRA Health Sciences, Inc. (KKR & Co., Inc.)
- Medpace Holdings, Inc.
- Medable, Inc.
- Clinical Ink, Inc. (G.I. Partners)
Unique Offerings
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific Virtual Clinical Trials Market by Study Type
Chapter 5. Asia Pacific Virtual Clinical Trials Market by Indication
Chapter 6. Asia Pacific Virtual Clinical Trials Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- IQVIA Holdings, Inc.
- ICON PLC
- Laboratory Corporation of America Holdings (Covance, Inc.)
- Dassault Systemes SE (Medidata Solutions, Inc.)
- Oracle Corporation
- Parexel International Corporation (Pamplona Capital Management)
- PRA Health Sciences, Inc. (KKR & Co., Inc.)
- Medpace Holdings, Inc.
- Medable, Inc.
- Clinical Ink, Inc. (G.I. Partners)
Methodology
LOADING...